KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Non Operating Income (2017 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Non Operating Income for 10 consecutive years, with -$456000.0 as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income fell 198.06% year-over-year to -$456000.0; the TTM value through Mar 2026 reached -$16.3 million, down 1171.63%, while the annual FY2025 figure was -$15.4 million, 1253.87% down from the prior year.
  • Non Operating Income hit -$456000.0 in Q1 2026 for Ionis Pharmaceuticals, up from -$16.3 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.2 million in Q2 2023 and bottomed at -$16.3 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$1.2 million, with a median of $277000.0 recorded in 2024.
  • Year-over-year, Non Operating Income skyrocketed 6133.33% in 2022 and then tumbled 5493.05% in 2025.
  • Ionis Pharmaceuticals' Non Operating Income stood at $649000.0 in 2022, then tumbled by 2238.52% to -$13.9 million in 2023, then skyrocketed by 102.18% to $302000.0 in 2024, then crashed by 5493.05% to -$16.3 million in 2025, then skyrocketed by 97.2% to -$456000.0 in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$456000.0, -$16.3 million, and $363000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.